PMDA established the Science Board on May 14th 2012, as a high-level consultative body which discusses scientific aspects of pharmaceuticals, medical devices and regenerative medical products review.
The purposes of the Science Board are, advancing regulatory science and evaluate products with advanced science and technology in appropriate manner by enhancing cooperation and communication with academia and medical institutions, based on PMDA's philosophy to deliver safe and effective drugs, medical devices and regenerative medical products to the people and further promotion of medical innovations.
The 7th Term (FY2024, FY2025)
- Subcommittee on Software as a Medical Device Utilizing AI and Machine Learning
- Subcommittee on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes
- Subcommittee on AI (Artificial Intelligence)
- Subcommittee on Pharmaceuticals Development
- Subcommittee on Rare Cancers
- Subcommittee on Evaluation of Medical Devices in Pediatric Use
- Subcommittee on Placebo-controlled Studies
- Subcommittee on Application of Numerical Analysis to Non-clinical Evaluation
- Subcommittee on Non-clinical Studies
- CPC (Cell Processing Center) Subcommittee
- Pharmaceuticals Subcommittee
- Bio-products Subcommittee
- Medical Devices Subcommittee
- Cellular and Tissue-based Products Subcommittee
(note) Subcommittees are listed based on when the outcome documents are published.